IP Library Granted Patent US 12,371,650
Granted Patent B2
US 12,371,650 · App. 18/538,702 · Granted Jul 29, 2025

Method and system for providing buffer solutions

Inventor: Tristan Wilkins (Newmarket, NH)
Assignee: LONZA LTD
C12M41/32C12M23/44C12M29/00C12M37/00C12M41/36C12M43/00B67D7/0294
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,650
App. No.
18/538,702
Granted
Jul 29, 2025
Kind
B2
Abstract

A method for delivering a processing solution includes providing a concentrated processing solution in a bioprocess container, the concentrated processing solution being produced at a first site. The method also includes combining the concentrated processing solution with a biopolymer containing solution produced in a bioreactor at a second site different from the first site. In some embodiments, the processing solution is a buffer for processing products of cells cultured in a bioreactor. A system and a pharmaceutical production facility for carrying out the method is also provided.

Claims (24)

1. A system for delivering a processing solution, the system comprising:

a bioprocess container containing a concentrated processing solution, the bioprocess container having an inner layer for contacting the concentrated processing solution and an outer layer configured to support the inner layer, the bioprocess container configured to contain the concentrated processing solution when the bioprocess container is transported from a first site to a second site;

a processing area having at least one processing unit at the second site different from the first site; and

a pipe connecting the bioprocess container to the at least one processing unit at the second site, the pipe having a valve to:

allow the concentrated processing solution to flow from the bioprocess container to the at least one processing unit to combine the concentrated processing solution with a biopolymer containing solution produced in the at least one processing unit, and

maintain a sterile condition of the processing unit when the bioprocess container is disconnected from the pipe,

wherein the processing solution is at least one of a buffer and media.

2. The system of claim 1 , further comprising a controller connected to the at least one processing unit, wherein the concentrated processing solution is provided based on a determination by the controller that the processing solution is required when the determination is communicated from the second site to the first site.

3. The system of claim 1 , wherein the system is configured to dilute the concentrated processing solution prior to combining with the biopolymer containing solution.

4. The system of claim 1 , further comprising a controller configured to determine a bioburden of the processing solution.

5. The system of claim 1 , comprising a dilution liquid supply, wherein the concentrated processing solution from the bioprocess container and at least one of water and buffer from the dilution liquid supply is added to an inlet of an inline processing solution dilution system to result in a diluted processing solution.

6. The system of claim 1 , wherein the processing solution is one of Tris, Tris-Base, Tricine, HEPES, MOPS, PIPES, TAPS, bicine, BES, TES, cacodylate, MES, acetate, MKP, ADA, ACES, glycinamide, acetamidoglycine, acetic acid, citric acid, glycine, glycine glycinate, sodium phosphate, ethanol, hydrochloric acid, sodium hydroxide, guanidinium chloride, guanidine hydrochloride, sodium chloride, and a combination of any of these.

7. A pharmaceutical production facility comprising:

at least one bioprocess container having an inner layer for contacting a concentrated processing solution and an outer layer configured to support the inner layer, the at least one bioprocess container configured to contain the concentrated processing solution when the at least one bioprocess container is transported from a first site to a second site;

a buffer storage area capable of receiving the at least one bioprocess container;

a processing area having at least one processing unit;

a wall separating the buffer storage area from the processing area; and

at least one pipe having a first end in the buffer storage area and a second end in the processing area, the first end configured to connect to the at least one bioprocess container and the second end configured to connect to the at least one processing unit,

wherein the at least one pipe has a valve to maintain a sterile condition of the at least one processing unit when the at least one bioprocess container is disconnected from the at least one pipe.

8. The pharmaceutical production facility of claim 7 , further comprising:

a platform in the buffer storage area, the platform being configured to support the at least one bioprocess container, the at least one bioprocess container including a plurality of bioprocess containers, the platform having a first level configured to support at least one bioprocess container of the plurality of bioprocess containers and a second level configured to support at least one bioprocess container of the plurality of bioprocess containers,

wherein the platform is configured to allow a user to place a bioprocess container of the plurality of bioprocess containers onto the platform using a forklift, and the platform being configured to allow a user to remove the respective bioprocess container from the platform using the forklift.

9. The pharmaceutical production facility of claim 8 , further comprising a plurality of inlets spaced apart along the platform, each inlet being connected to the at least one pipe, and each inlet being configured to be connected to an outlet of a bioprocess container of the plurality of bioprocess containers, wherein the processing area is configured as a cleanroom environment.

10. The pharmaceutical production facility of claim 7 , wherein the valve is positioned within or adjacent to the wall separating the buffer storage area from the processing area.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2023
From: WILKINS, TRISTAN
To: LONZA LTD
Reel/Frame 065861/0813 →
Continuity (4)
Continuation 16876498 · May 18, 2020
Continuation 15667387 · Aug 2, 2017
Provisional Application 62370041 · Aug 2, 2016
Related Publication 20240132830A1 · Apr 25, 2024
References Cited (58)
US 5272071A · Chappel · 1993 [cited by applicant]
US 5474411A · Schoenfeld et al. · 1995 [cited by applicant]
US 5633162A · Keen et al. · 1997 [cited by applicant]
US 5656491A · Cassani et al. · 1997 [cited by applicant]
US 6326193B1 · Liu et al. · 2001 [cited by applicant]
US 6393775B1 · Staschik · 2002 [cited by applicant]
US 6703199B1 · Koide · 2004 [cited by applicant]
US 7515994B2 · Bellafiore et al. · 2009 [cited by applicant]
US 7629167B2 · Hodge et al. · 2009 [cited by applicant]
US 8298054B2 · Hodge et al. · 2012 [cited by applicant]
US 9158345B1 · Rice et al. · 2015 [cited by applicant]
US 9946902B2 · Nyffeler et al. · 2018 [cited by applicant]
US 20010047628A1 · Mouton et al. · 2001 [cited by applicant]
US 20020189173A1 · Staschik · 2002 [cited by applicant]
US 20040079691A1 · Jowett · 2004 [cited by applicant]
US 20050193643A1 · Pettus · 2005 [cited by examiner]
US 20050205658A1 · Baker et al. · 2005 [cited by applicant]
US 20050235581A1 · Cohen et al. · 2005 [cited by applicant]
US 20090037031A1 · George et al. · 2009 [cited by applicant]
US 20090300998A1 · Ablett · 2009 [cited by applicant]
US 20090305626A1 · Hope · 2009 [cited by applicant]
US 20110240497A1 · Dechene et al. · 2011 [cited by applicant]
US 20110258837A1 · Scannon et al. · 2011 [cited by applicant]
US 20120077429A1 · Wernimont et al. · 2012 [cited by applicant]
US 20130067721A1 · Scannon et al. · 2013 [cited by applicant]
US 20130109291A1 · Holtz et al. · 2013 [cited by applicant]
US 20130164400A1 · Knopov · 2013 [cited by examiner]
US 20130233532A1 · Imwalle et al. · 2013 [cited by applicant]
US 20130280797A1 · Rao et al. · 2013 [cited by applicant]
US 20140335566A1 · Guerini et al. · 2014 [cited by applicant]
US 20150036266A1 · Emert et al. · 2015 [cited by applicant]
US 20150101264A1 · Jornitz · 2015 [cited by applicant]
US 20160105988A1 · Englert et al. · 2016 [cited by applicant]
US 20160312485A1 · Wilson et al. · 2016 [cited by applicant]
US 20160376784A1 · Timur · 2016 [cited by applicant]
US 20170008752A1 · Tuohey · 2017 [cited by examiner]
CN 1654282A · 2005 [cited by applicant]
CN 101981600A · 2011 [cited by applicant]
DE 9014558U1 · 1991 [cited by applicant]
EP 2103548 · 2009 [cited by applicant]
JP H04368568A · 1992 [cited by applicant]
JP 2008041102A · 2008 [cited by applicant]
JP 2011509685A · 2011 [cited by applicant]
JP 2011518370A · 2011 [cited by applicant]
JP 2012513649A · 2012 [cited by applicant]
WO 0129058 · 2001 [cited by applicant]
WO 0196584 · 2001 [cited by applicant]
WO 2015117883A1 · 2015 [cited by applicant]
WO 2015117883 · 2015 [cited by applicant]
Norris, “Method for Evaluating Bio-Container Transportation Applications,” BioProcess International. Jul. 1, 2008. [cited by applicant]
Fritchman et al. “Strategic Outsourcing of Media Design and Cell Culture Media Manufacturing” Biopharm International (2009) vol. 22, No. 9, pp. 18-19. [cited by applicant]
Haigney “Integrating Single-Use Systems in Pharma Manufacturing” Pharmatech (2016) vol. 40, No. 6, pp. 1-5; Retrieved from the Internet at http://www.pharmtech.com/inteoratina-single-use-systems-aharma-manufacturing; Re… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/043768 dated Nov. 13, 2017. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/045162 dated Nov. 17, 2017. [cited by applicant]
Shukla et al. “Single-use disposable technologies for biopharmaceutical manufacturing” Trends in Biotechnology (2013) vol. 31, No. 3, pp. 147-154. [cited by applicant]
All Foreign Patent Documents and Non-Patent Literature is provided in priority U.S. Appl. No. 15/667,387. [cited by applicant]
Haigney, “Integrating Single-Use Systems in Pharma Manufacturing,” Pharmaceutical Technology 40(6), pp. 42-44 (Jun. 2, 2016). [cited by applicant]
Patterson, “Automated In-Line Dilution—A QbD Manufacturing Method”, Journal of GXP Compliance, vol. 12, pp. 20-33, Nov. 5, 2008. [cited by applicant]